Pfizer Sues Sandoz to Block Copies of Inlyta Cancer Drug (1)

Sandoz Inc.’s proposed generic version of Inlyta infringes a patent for the kidney-cancer chemotherapy treatment, Pfizer Inc. said in a federal lawsuit.

Pfizer alleges Sandoz’s copies infringe US Patent No. 8,791,140, which covers specific crystalline forms of Inlyta’s active ingredient, axitinib, according to a complaint filed Tuesday in the US District Court for the District of Delaware. Sandoz, a unit of Sandoz Group AG, declined to comment.

• The ‘140 patent expires in June 2031, according to Inlyta’s entry in the US Food and Drug Administration’s registry of approved drugs, the Orange Book. Pfizer seeks orders blocking copies until then. ...